Approved |
YABS0071 |
08/16/2023 |
Tafolecimab |
IBI306 |
SINTBILO |
mAb human |
Naked monospecific |
Full length Ab |
None |
PCSK9 |
IgG2 |
kappa |
None |
None |
None |
IBI306 is a fully human monoclonal antibody that binds proprotein convertase substilisin/kexin type 9 (PCSK9), preventing its interaction with the low-density lipoprotein cholesterol receptor (LDL-R) and thereby restoring LDL-R recycling and low-density lipoprotein cholesterol(LDL-C)uptake |
None |
None |
Approved China |
Active |
11/27/2017 |
03/07/2019 |
12/20/2019 |
Hypercholesterolemia |
Metabolic disorders |
Innovent Biologics (Suzhou) Co. Ltd. |
None |
None |
2023 |
— |
— |
Tafolecimab |
China |
Asia |
https://www.innoventbio.com/AboutUs/ContactUs |
Approved |
YABS0072 |
03/12/2025 |
Sintilimab |
IBI308 |
Tyvyt |
mAb human |
Naked monospecific |
Full length Ab |
None |
PD-1 |
IgG4 |
kappa |
None |
None |
None |
Immune checkpoint inhibitor |
Adimab technology (yeast display) |
None |
Approved China |
Active |
09/15/2016 |
— |
09/01/2017 |
Liver cancer, gastric cancer, solid tumors, non-small cell lung cancer, Esophageal cancer, Hodgkin's lymphoma |
Cancer |
Innovent Biologics |
Eli Lilly |
None |
2018 |
— |
— |
Sintilimab |
United States of America |
North America |
https://www.innoventbio.com/AboutUs/ContactUs |
Approved |
YABS0073 |
09/27/2019 |
Rituximab |
IDEC-C2B8 |
Rituxan |
mAb chimeric |
Naked monospecific |
Full length Ab |
None |
CD20 |
IgG1 |
kappa |
None |
None |
None |
None |
None |
None |
Approved EU, US, Japan, Australia |
Active |
12/15/1992 |
11/15/1993 |
04/15/1995 |
Non-Hodgkin's B-cell lymphoma |
Cancer |
Biogen Idec |
Schering, Genentech |
None |
1997 |
02/28/1997 |
11/26/1997 |
Rituximab |
United States of America |
North America |
https://www.biogen.com/company/contact-us.html |
Approved |
YABS0074 |
01/01/2018 |
Ibritumomab tiuxetan |
IDEC-Y2B8 |
Zevalin |
mAb murine |
Radioimmunotherapy, RIC |
Full length Ab conjugate |
None |
CD20 |
IgG1 |
kappa |
None |
None |
Undisclosed |
None |
Mouse origin |
None |
Approved EU, US, Japan |
Active |
11/24/1992 |
05/20/1998 |
02/24/1998 |
Non-Hodgkin's B-cell lymphoma |
Cancer |
Biogen Idec |
Eli Lilly |
None |
2002 |
11/01/2000 |
02/19/2002 |
Ibritumomab tiuxetan |
United States of America |
North America |
https://www.biogen.com/company/contact-us.html |
Approved |
YABS0075 |
05/01/2014 |
Ramucirumab |
IMC-1121B |
Cyramza |
mAb human |
Naked monospecific |
Full length Ab |
None |
VEGFR2 |
IgG1 |
kappa |
None |
None |
None |
VEGF binds to VEGFR-2 (KDR); produced in NS0 |
Phage display-DYAX |
None |
Approved EU, US, Japan, Australia |
Active |
12/15/2004 |
— |
08/15/2008 |
Gastric Cancer; Adenocarcinoma, Hepatocellular Carcinoma, breast cancer, Colorectal Cancer, Non-Small Cell Lung Cancer, Prostate Cancer, melanoma, Stomach Cancer; Esophageal Cancer, Carcinoma of Urinary Tract; Urethral Carcinoma; Carcinoma of Ureter; Carcinoma of Renal Pelvis |
Cancer |
Eli Lilly and Company |
None |
None |
2014 |
08/23/2013 |
04/21/2014 |
Ramucirumab |
United States of America |
North America |
https://www.lilly.com/contact-us |
Approved |
YABS0076 |
11/24/2015 |
Necitumumab |
IMC-11F8 |
Portrazza |
mAb human |
Naked monospecific |
Full length Ab |
None |
EGFR |
IgG1 |
kappa |
None |
None |
None |
None |
Phage display-DYAX |
None |
Approved EU, US, Japan |
Active |
11/15/2004 |
— |
11/15/2009 |
Non Small Cell Lung Cancer, Metastatic Colorectal Cancer, Solid Tumors |
Cancer |
Eli Lilly and Company |
AstraZeneca, Shire |
None |
2015 |
12/02/2014 |
11/24/2015 |
Necitumumab |
United States of America |
North America |
https://www.lilly.com/contact-us |
Approved |
YABS0077 |
01/06/2018 |
Cetuximab |
IMC-C225, C-225 |
Erbitux |
mAb chimeric |
Naked monospecific |
Full length Ab |
None |
EGFR |
IgG1 |
kappa |
None |
None |
None |
None |
None |
None |
Approved EU, US, Japan, Australia |
Active |
11/15/1994 |
05/15/1995 |
03/09/1999 |
Head and neck cancer, colorectal, non-small cell lung cancer |
Cancer |
Imclone Systems |
Eisai, Cambridge Antibody Technology, Basf Pharma |
None |
2003 |
08/14/2003 |
02/12/2004 |
Cetuximab |
United States of America |
North America |
https://pitchbook.com/profiles/company/41262-76#overview |
Approved |
YABS0078 |
02/06/2025 |
Tebentafusp |
IMCgp100 |
KIMMTRAK |
mAb - source TBD |
Bispecific, Immunoconjugate |
Fragment fusion |
scFv-TCR |
CD3, gp100 |
None |
TBD |
None |
None |
T cell receptor |
Monoclonal T Cell Receptor Anti-CD3 scFv Fusion Protein; soluble protein comprises a high- affinity T cell receptor (TCR) specific to a peptide sequence from the gp100 antigen, which is presented on melanoma tumour cells by HLA-A2, fused to an anti-CD3 single chain antibody fragment. |
None |
None |
Approved EU, US, Canada, UK, Australia |
Active |
09/15/2010 |
10/15/2013 |
10/16/2017 |
Uveal melanoma, malignant melanoma |
Cancer |
Immunocore Ltd |
AstraZeneca |
None |
2022 |
06/23/2021 |
01/25/2022 |
Tebentafusp, tebentafusp-tebn |
United Kingdom |
Europe |
https://www.immunocore.com/contact-us |
Approved |
YABS0079 |
02/06/2025 |
Mirvetuximab soravtansine |
IMGN853 |
ELAHERE |
mAb humanized |
ADC |
Full length Ab conjugate |
None |
FR alpha |
IgG1 |
kappa |
Sulfo-SPDB, Cleavable linker |
3.3 to 4 drugs per mAb |
Tubulin inhibitor, DM4 maytansine |
M9346A-sulfo-SPDB-DM4 is denoted as IMGN853. DAR range is reported for multiple ADC, including IMGN853 in Ab et al (https://aacrjournals.org/mct/article/14/7/1605/132016/IMGN853-a-Folate-Receptor-FR-Targeting-Antibody). A humanized derivative of MOv19 (denoted M9346A) serves as the antibody moiety of IMGN853. |
None |
None |
Approved EU, US |
Active |
03/15/2012 |
01/15/2016 |
01/15/2017 |
Epithelial malignancies e.g., ovarian cancer adenocarcinoma |
Cancer |
AbbVie |
None |
None |
2022 |
03/28/2022 |
11/14/2022 |
Mirvetuximab soravtansine, mirvetuximab soravtansine-gynx |
United States of America |
North America |
https://www.immunogen.com/ |
Approved |
YABS0080 |
02/06/2025 |
Sacituzumab govitecan |
IMMU-132, hRS7-SN-38 |
Trodelvy |
mAb humanized |
ADC |
Full length Ab conjugate |
None |
TROP-2 |
IgG1 |
kappa |
CL2A, Cleavable linker |
7 to 8 drugs per mAb |
Topoisomerase I inhibitor, SN38 (irinotecan active metabolite) |
Sacituzumab govitecan-hziy is a Trop-2 directed antibody and topoisomerase inhibitor conjugate, composed of the following three components: a) the humanized monoclonal antibody, hRS7 IgG1κ (also called sacituzumab), which binds to Trop-2 (the trophoblast cell-surface antigen-2); b) the drug SN-38 (irinotecan active metabolite), a topoisomerase inhibitor; c) a hydrolysable linker (called CL2A), which links the humanized monoclonal antibody to SN-38. The recombinant monoclonal antibody is produced by mammalian (murine myeloma) cells, while the small molecule components SN-38 and CL2A are produced by chemical synthesis. Sacituzumab govitecan-hziy contains on average 7 to 8 molecules of SN-38 per antibody molecule. Sacituzumab govitecan-hziy has a molecular weight of approximately 160 kilodaltons. |
None |
None |
Approved EU, US, Australia |
Active |
06/01/2012 |
— |
10/12/2017 |
Triple negative breast cancer, metastatic urothelial cancer, Advanced Epithelial Cancers |
Cancer |
Immunomedics Inc. |
Seagen Inc. |
None |
2020 |
05/18/2018 |
04/22/2020 |
Sacituzumab govitecan, sacituzumab govitecan-hziy |
United States of America |
North America |
https://www.gilead.com/utility/contact |